Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs

[1]  M. Khatami.  Inflammation, Aging and Cancer , 2017, Springer International Publishing.

[2]  S. Pautler,et al.  Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[3]  B. Seliger,et al.  The role of microRNAs in the control of innate immune response in cancer. , 2014, Journal of the National Cancer Institute.

[4]  E. Toussirot,et al.  Vaccination and Induction of Autoimmune Diseases. , 2015, Inflammation & allergy drug targets.

[5]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[6]  M. Khatami.  Developmental Phases of Inflammation-Induced Massive Lymphoid Hyperplasia and Extensive Changes in Epithelium in an Experimental Model of Allergy: Implications for a Direct Link Between Inflammation and Carcinogenesis , 2005, American journal of therapeutics.

[7]  M A Konerding,et al.  Microvascular corrosion casting in the study of tumor vascularity: a review. , 1995, Scanning microscopy.

[8]  H. Maeda,et al.  A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next‐Generation Chemotherapeutics and Photodynamic Therapy—Problems, Solutions, and Prospects , 2016, Microcirculation.

[9]  M. Khatami.  Unresolved Inflammation and Cancer: Loss of Natural Immune Surveillance as the Correct ‘Target’ for Therapy! Seeing the ‘Elephant’ in the Light of Logic , 2011, Cell Biochemistry and Biophysics.

[10]  H. Burstein.  Bevacizumab for advanced breast cancer: all tied up with a RIBBON? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Khatami.  Cyclooxygenase inhibitor ketorolac or mast cell stabilizers: immunologic challenges in cancer therapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Ji-Seon Lee,et al.  Involvement of NADPH Oxidase-mediated Generation of Reactive Oxygen Species in the Apototic Cell Death by Capsaicin in HepG2 Human Hepatoma Cells , 2004, Free radical research.

[13]  H. Maeda,et al.  Protection from inflammatory bowel disease and colitis-associated carcinogenesis with 4-vinyl-2,6-dimethoxyphenol (canolol) involves suppression of oxidative stress and inflammatory cytokines. , 2013, Carcinogenesis.

[14]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[15]  A. Darzi,et al.  Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer , 2017, Annals of surgical oncology.

[16]  R. Johnson.  Screening methods in antineoplastic drug discovery. , 1990, Journal of the National Cancer Institute.

[17]  H. Maeda.  Enhanced Permeability and Retention Effect in Relation to Tumor Targeting , 2011 .

[18]  H. Maeda,et al.  Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein. , 1987, Cancer research.

[19]  T. Lammers.  Drug delivery research in Europe. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[20]  H. Maeda,et al.  Nitric oxide and virus infection , 2000, Immunology.

[21]  T. Eberlein,et al.  Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. , 1982, The Journal of experimental medicine.

[22]  H. Maeda,et al.  Formation of abasic sites in DNA by t-butyl peroxyl radicals: implication for potent genotoxicity of lipid peroxyl radicals. , 2000, Cancer letters.

[23]  M. Khatami.  Cancer Statistics and Concerns for Safety of Drugs or Vaccines: Increased Population of Drug-Dependent Sick Society! , 2017 .

[24]  A. Geldof,et al.  Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer. , 2014, Anticancer research.

[25]  S. Clarke,et al.  Inflammation and Cancer: Causes and Consequences , 2010, Clinical pharmacology and therapeutics.

[26]  Jessup Jm.  Cathepsin B and other proteases in human colorectal carcinoma. , 1994 .

[27]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[28]  Mitchell Kronenberg,et al.  Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.

[29]  Y. Takahashi,et al.  Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin. , 1983, The Journal of antibiotics.

[30]  H. Maeda,et al.  Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes , 1987, Cancer.

[31]  M. Khatami.  Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis! , 2014, Cancers.

[32]  H. Maeda,et al.  Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. , 2005, Bioconjugate chemistry.

[33]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[34]  M. Khatami.  Inflammation, Aging, and Cancer: Tumoricidal Versus Tumorigenesis of Immunity , 2009, Cell Biochemistry and Biophysics.

[35]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[36]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[37]  H. Maeda,et al.  Pathophysiological Effects of High-Output Production of Nitric Oxide , 2000 .

[38]  M. Taniwaki,et al.  Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Maeda.  Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[40]  J. Donnelly,et al.  Induction and down-regulation of conjunctival type-I hypersensitivity reactions in guinea pigs sensitized topically with fluoresceinyl ovalbumin. , 1985, Ophthalmic research.

[41]  A. Kalergis,et al.  New clinical advances in immunotherapy for the treatment of solid tumours , 2015, Immunology.

[42]  Heidi Ledford,et al.  Translational research: 4 ways to fix the clinical trial , 2011, Nature.

[43]  R. Mayer,et al.  Targeted therapy for advanced colorectal cancer--more is not always better. , 2009, The New England journal of medicine.

[44]  K. Ulbrich,et al.  Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. , 2016, Molecular pharmaceutics.

[45]  V. Singh,et al.  Inflammation, microenvironment, and the immune system in cancer progression. , 2009, Current pharmaceutical design.

[46]  G. Sledge.  Anti-vascular endothelial growth factor therapy in breast cancer: game over? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Maeda,et al.  Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application , 2009, Cancer science.

[48]  H. Maeda,et al.  Superoxide generation mediated by 8-nitroguanosine, a highly redox-active nucleic acid derivative. , 2003, Biochemical and biophysical research communications.

[49]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[50]  M. Hensley.  Big costs for little gain in ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  H. Maeda,et al.  Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. , 2009, Japanese journal of clinical oncology.

[52]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  H. Maeda,et al.  Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. , 1989, Science.

[54]  M. Khatami.  'Yin and Yang' in inflammation: duality in innate immune cell function and tumorigenesis. , 2008, Expert opinion on biological therapy.

[55]  M. Khatami.  Inflammation, Chronic Diseases and Cancer - Cell and Molecular Biology, Immunology and Clinical Bases , 2012 .

[56]  Paolo Boffetta,et al.  Adult cancer clinical trials that fail to complete: an epidemic? , 2014, Journal of the National Cancer Institute.

[57]  Hiroshi Maeda,et al.  Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. , 2015, Advanced drug delivery reviews.

[58]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[59]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[60]  W. Decker,et al.  Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. , 2009, Cytokine & growth factor reviews.

[61]  K. Ulbrich,et al.  Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[62]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[63]  M. Khatami,et al.  Histamine and prostacyclin. Primary and secondary release in allergic conjunctivitis. , 1991, Investigative ophthalmology & visual science.

[64]  M. Millenson,et al.  Cancer- and chemotherapy-induced anemia. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[65]  J. H. Scarffe,et al.  Cancer Medicine , 1982, British Journal of Cancer.

[66]  H. Maeda,et al.  Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth , 1996, Cancer.

[67]  H. Maeda,et al.  Generation of drug‐resistant mutants of Helicobacter pylori in the presence of peroxynitrite, a derivative of nitric oxide, at pathophysiological concentration , 2009, Microbiology and immunology.

[68]  E. Sausville,et al.  Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate , 2013, Cancer Chemotherapy and Pharmacology.

[69]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[70]  T. Okano,et al.  Development of the polymer micelle carrier system for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[71]  C J Gomer,et al.  Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1990, Cancer research.

[72]  H. Maeda,et al.  Superoxide radical generation from heterocyclic amines. , 1995, Princess Takamatsu symposia.

[73]  M. Khatami.  Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint? , 2016, Clinical and Translational Medicine.

[74]  A. Lièvre,et al.  Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues , 2015, Cancer.

[75]  H. Maeda,et al.  Nitric oxide and oxygen radicals in infection, inflammation, and cancer. , 1998, Biochemistry. Biokhimiia.

[76]  O. Auerbach,et al.  Neoplasms of the testis. , 1946, The Journal of urology.

[77]  H. Maeda,et al.  Nitric Oxide as an Endogenous Mutagen for Sendai Virus without Antiviral Activity , 2004, Journal of Virology.

[78]  T. Fojo,et al.  Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. , 2012, Journal of the National Cancer Institute.

[79]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[80]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[81]  Kinam Park.  Questions on the role of the EPR effect in tumor targeting. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[82]  W. Coley.  The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). , 1910, Proceedings of the Royal Society of Medicine.

[83]  M. Khatami.  Unresolved inflammation: ‘immune tsunami’ or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer , 2011, Expert opinion on biological therapy.

[84]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[85]  H. Maeda,et al.  Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls , 2015, Expert opinion on drug delivery.

[86]  G. Storme,et al.  Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. , 1998, Cancer research.

[87]  H. Maeda,et al.  Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. , 1980, European journal of cancer.

[88]  H. Maeda.  Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[89]  H. Maeda,et al.  Synthesis and therapeutic effect of styrene–maleic acid copolymer-conjugated pirarubicin , 2015, Cancer science.

[90]  H. Yasuda,et al.  Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. , 2008, Nitric oxide : biology and chemistry.

[91]  K. Kida,et al.  Antioxidative and antimutagenic activities of 4-vinyl-2,6-dimethoxyphenol (canolol) isolated from canola oil. , 2004, Journal of agricultural and food chemistry.

[92]  H. Maeda,et al.  Evidence of Direct Generation of Oxygen Free Radicals from Heterocyclic Amines by NADPH/Cytochrome P‐450 Reductase in vitro , 1992, Japanese journal of cancer research : Gann.

[93]  J. Donnelly,et al.  Massive follicular lymphoid hyperplasia in experimental allergic conjunctivitis. Local antibody production. , 1989, Archives of ophthalmology.

[94]  Joseph W. Nichols,et al.  EPR: Evidence and fallacy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[95]  J. Lenzer,et al.  Why cancer screening has never been shown to “save lives”—and what we can do about it , 2016, BMJ : British Medical Journal.

[96]  M. Millenson,et al.  Cancer- and chemotherapy-induced anemia. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[97]  K. Ulbrich,et al.  Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin , 2015, Future science OA.

[98]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[99]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[100]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[101]  Jennifer L. Clarke,et al.  Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. , 2014, Seminars in radiation oncology.

[102]  H. Maeda,et al.  4‐Vinyl‐2,6‐dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori‐infected carcinogen‐treated Mongolian gerbils , 2007, International journal of cancer.

[103]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[104]  T. Fojo,et al.  Why do phase III clinical trials in oncology fail so often? , 2012, Journal of the National Cancer Institute.

[105]  So much effort, so little progress? , 2014, Journal of the National Cancer Institute.

[106]  G. Sinha.  Expensive cancer drugs with modest benefit ignite debate over solutions. , 2008, Journal of the National Cancer Institute.

[107]  K. Ulbrich,et al.  Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[108]  R. Duncan.  Polymer-Drug Conjugates: Targeting Cancer , 2002 .

[109]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[110]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[111]  J. Furuse,et al.  Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine , 2017, Cancer science.

[112]  J. Jessup.  Cathepsin B and other proteases in human colorectal carcinoma. , 1994, The American journal of pathology.

[113]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[114]  R. Weinberg.  Coming Full Circle—From Endless Complexity to Simplicity and Back Again , 2014, Cell.

[115]  S. Gabriel,et al.  Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.

[116]  Jennifer H. Grossman,et al.  Nanotechnology in Cancer Medicine , 2012 .

[117]  H. Kubo,et al.  Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  H. Maeda,et al.  Viral mutation accelerated by nitric oxide production during infection in vivo. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[120]  S. Bates,et al.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[121]  H. Maeda,et al.  Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[122]  J. Sejvar,et al.  Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. , 2011, Vaccine.

[123]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[124]  H. Maeda,et al.  In vitro and in vivo evaluation of tumor targeting styrene‐maleic acid copolymer‐pirarubicin micelles: Survival improvement and inhibition of liver metastases , 2010, Cancer science.

[125]  Thomas J. Smith,et al.  Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  Tonglei Li,et al.  Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[127]  F Lechenault,et al.  Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. , 1998, Journal of pharmaceutical sciences.

[128]  G. Alarcón,et al.  Vasculitis as an adverse event following immunization - Systematic literature review. , 2016, Vaccine.

[129]  J. Witjes.  Management of BCG failures in superficial bladder cancer: a review. , 2006, European urology.

[130]  J. Weber.  Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. , 2010, Seminars in oncology.

[131]  Harvey V. Fineberg,et al.  The Swine Flu Affair: Decision-Making on a Slippery Disease , 1979 .

[132]  Q. Shen,et al.  Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. , 2014, Cancer letters.

[133]  Susan M. Chang,et al.  Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. , 2014, Neuro-oncology.

[134]  C. Unger,et al.  Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates , 1997 .

[135]  M. Khatami.  Immune Surveillance in Health and Diseases of Aging: Definitions of Acute and Chronic Inflammation [Yin and Yang] , 2017 .

[136]  K. Ulbrich,et al.  New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[137]  M. Khatami.  Safety concerns and hidden agenda behind HPV vaccines: another generation of drug-dependent society? , 2016, Clinical and Translational Medicine.

[138]  H. Maeda,et al.  Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation , 2007, Journal of drug targeting.

[139]  Hiroshi Maeda,et al.  The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect , 2013, Cancer science.

[140]  Robert M. Hoffman,et al.  Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic , 2004, Investigational New Drugs.

[141]  Alison Day,et al.  'An American Tragedy'. The Cutter Incident and its Implications for the Salk Polio Vaccine in New Zealand 1955-1960 , 2022, Health and history.

[142]  H. Maeda,et al.  Free radical generation from heterocyclic amines by cytochrome b5 reductase in the presence of NADH. , 1999, Cancer letters.